Biosafety and selectable markers
Biosafety and selectable markers
复制标题
DOI：
10.1196/annals.1409.002
复制
发表时间：
2007-01-01
期刊：
影响因子：
--
通讯作者：
Nano, Francis E.
中科院分区：
文献类型：
--
作者：
Titball, Richard W.;Sjostedt, Anders;Nano, Francis E.
土拉弗朗西斯菌（Francisella tularensis）F.土拉菌）是已知传染性最强的病原体之一。虽然由这种细菌引起的疾病在适当的抗生素治疗下很少是致命的，但它通常会使人严重衰弱。实验室工作与F。土拉热病造成重大危害，因此，在任何处理这种病原体的组织中，必须有适当的实验室设施、训练有素的人员和适当的工作做法。人类强毒株的工作应在3级防护水平下进行。疫苗在保护与F.土拉热，但活疫苗株（LVS）疫苗目前尚未获准用于人类。由于抗生素治疗是人类兔热病治疗的核心，因此应仔细选择用于遗传操作研究的抗生素耐药性标记。
Francisella tularensis (F. tularensis) is one of the most infectious pathogens known. Although the disease caused by this bacterium is rarely fatal with appropriate antibiotic therapy, it is often severely debilitating. Laboratory work with F. tularensis poses a significant hazard, and it is essential that appropriate laboratory facilities, trained personnel, and suitable working practices are in place in any organization working with this pathogen. Work with human virulent strains should be carried out at containment level 3. Vaccines play an important potential role in the protection of individuals working with F. tularensis, but the live vaccine strain (LVS) vaccine is not currently licensed for use in humans. Because antibiotic therapy is central to the treatment of human tularemia, antibiotic resistance markers for use in genetic manipulation studies should be carefully selected.